The MHRA last week launched a consultation on statutory fees proposals for April 2025 until March 2027. Unsurprisingly, the trajectory is upwards – in some cases (such as clinical trials) significantly.
BIVDA’s Head of Policy and Programmes, Paul Fisher noted, “These proposed increases will disproportionately impact SMEs – the sector that the government and NHS recognise as a key part of the UK health economy. Given the MHRA has had challenges meeting its targets, particularly with regards to clinical trials, any increase is doubly unwelcome.”
Please provide your initial feedback on the proposed changes by close of business on 27th September to regulatory@bivda.org.uk.
Although the consultation closes 24th October, we will need time to collate responses and raise the BIVDA response to this consultation.
